Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: The Pivotal Phase 3 ADORING Clinical Program

Main Article Content

Lawrence Eichenfeld
Jonathan Silverberg
Robert Bissonnette
Anna Tallman
David Rubenstein
Stephen Piscitelli
John Jett

Keywords

tapinarof, atopic dermatitis, ADORING trial

Abstract

N/A

References

1. Weidinger S & Novak N. Lancet. 2016;387:1109–1122;

2. Bieber T. N Engl J Med. 2008;358:1483–1494;

3. Carroll CL, et al. Pediatr Dermatol. 2005;22:192–199;

4. Lewis-Jones S. Int J Clin Pract. 2006;60:984–992;

5. National Eczema Association. https://nationaleczema.org/research/eczema-facts/.
Accessed May 2021;

6. Bissonnette R, et al. J Am Acad Dermatol. 2021;84:1059–1067;

7. Dermavant DOF [DMVT-505 Th2 Polarization; Apr 2015];

8. Dermavant DOF [DMVT-505 AD Mouse Model; Oct 2016];

9. Smith SH, et al. J Invest Dermatol. 2017;137:2110–2119;

10. Kim BE, et al. Allergy Asthma Immunol Res. 2018;10:207–215;

11. Peppers J, et al. J Am Acad Dermatol. 2019;80:89–98;

12. Paller A, et al. J Am Acad Dermatol. 2021;84:632–638

Most read articles by the same author(s)

<< < 1 2 3